Bioregulator Peptides: An Overview of the Khavinson Class for Researchers

Research use only. The bioregulator peptides described here are supplied as research-grade reference materials for laboratory use only, not for human or veterinary use.

Bioregulator peptides, particularly the Khavinson class of tissue-specific regulatory peptides, represent a niche research frontier with a substantial Russian-language literature base and emerging English-language coverage. For researchers entering the bioregulator space, understanding the discovery history, the tissue-specificity hypothesis, and the current state of mechanistic understanding is foundational.

This article surveys the Khavinson bioregulator class with attention to research-context framing, citation patterns, and methodological caveats.

At a Glance

• The Khavinson bioregulator class consists of short peptides (typically 2 to 6 residues) developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia.
• The defining hypothesis is tissue specificity: that short peptides extracted or synthesized from particular tissues regulate gene expression and function in those tissues.
• Major bioregulators in current research include Cartalax (cartilage), Vilon (thymus), Livagen (liver), Vesugen (vascular), Pinealon (pineal), Thymogen (thymus), and Epitalon (pineal).
• Mechanistic understanding remains partial. Animal model literature is extensive in Russian publications and growing in English peer-reviewed journals.
• Bioregulators have an unusually favorable position in research peptide economics due to short sequence length (lower synthesis cost) and low keyword difficulty (lower marketing competition).

Origins: The Khavinson Discovery and Tissue-Specificity Hypothesis

The bioregulator concept traces to research conducted at the Institute of Bioregulation and Gerontology in St. Petersburg, Russia, beginning in the 1970s.

Vladimir Khavinson: Russian Peptide Research Pioneer

Vladimir Khavinson and colleagues began with the observation that aqueous extracts of various organs (thymus, pineal gland, liver, prostate, others) contained low molecular weight peptide fractions that produced organ-specific effects in animal models. The original hypothesis was that these tissues produced and stored short regulatory peptides that contributed to homeostatic control of the source tissue.

Subsequent work attempted to isolate, sequence, and synthesize the active peptides. Several short peptides emerged from this program: dipeptides such as Vilon (Lys-Glu) and Vesugen (Lys-Glu-Asp), tripeptides such as Vilonin and others, tetrapeptides such as Cartalax (Ala-Glu-Asp-Pro) and Livagen (Lys-Glu-Asp-Ala) (Khavinson et al., 2002; PMID 12048635).

The Tissue-Specificity Concept: Can Peptides Regulate Specific Organs?

The central hypothesis of the Khavinson research program is that short peptides regulate gene expression in tissues from which they were originally isolated. The mechanism proposed involves penetration of the cell membrane, delivery to the nucleus, and direct or indirect effects on transcription of specific genes.

The hypothesis is provocative. Short peptides are not the canonical signaling molecules of receptor pharmacology, which usually involves longer ligands engaging cell surface receptors. The proposed mechanism (direct cell penetration and transcriptional regulation) is unusual and has received both supportive and skeptical commentary in the peer-reviewed literature.

Historical Context: Post-Soviet Research Traditions and Global Dissemination

The Khavinson program developed within the Russian and post-Soviet research tradition. Much of the foundational work was published in Russian-language journals with limited English translation, contributing to the relatively low Western awareness of this peptide class. English-language reviews have begun to summarize the work in recent years (Anisimov and Khavinson, 2010; PMID 20019471).

Also read: Peptides: A Comprehensive Research Reference Guide for Lab Scientists

Bioregulator Index

The compounds grouped under this heading are short peptides associated in the published literature with particular tissues. The table lists those stocked as reference materials, the tissue association reported for each, and the reference page for the compound. Tissue association is how the literature describes the compound; it is not a statement about any effect in an organism. Related compounds are indexed in the peptide reference library.

Compound	Tissue association in the literature	Reference page
Cardiogen	Cardiac tissue	Cardiogen
Pinealon	Pineal and neural tissue	Pinealon
Vilon	Thymic tissue	Vilon
Prostamax	Prostate tissue	Prostamax
Testagen	Testicular tissue	Testagen
Ovagen	Hepatic and ovarian tissue	Ovagen
Thymalin	Thymic tissue	Thymalin
Cartalax	Cartilage tissue	Cartalax
Epithalon	Pineal tissue	Epithalon

Epithalon

Epithalon is a four-residue peptide associated in the published literature with pineal tissue, and it is the most searched compound in this class. Recent work has examined telomerase upregulation and telomere length in human cell lines (Biogerontology, 2025; PMID 40908429), alongside a broader overview of the peptide’s reported properties (Int J Mol Sci, 2025; PMID 40141333). Earlier work in this area examined gene expression in cultured mesenchymal stem cells (Mol Biol Rep, 2020; PMID 32399807).

These are cell-culture and cell-line observations. They describe what was measured in those systems and do not describe an outcome in any organism. Molecular identity data is set out in the Epithalon chemical reference data, with a summary view in the Epitalon encyclopedia entry.

Major Bioregulator Peptides: Classification and Known Targets

The Khavinson program has produced more than two dozen named bioregulators. Several are widely studied and available as research chemicals.

Cartalax: Cartilage and Joint-Related Research

Cartalax is a tetrapeptide (Ala-Glu-Asp-Pro) studied in animal models of cartilage and connective tissue research. Reported effects in the source literature include modulation of chondrocyte gene expression and effects on extracellular matrix composition in cartilage tissue cultures.

Vilon: Thymus and Immune-Related Studies

Vilon is a dipeptide (Lys-Glu) studied in models of immune system aging. The literature reports effects on thymic function in aged animal models, with proposed mechanisms involving modulation of immune cell gene expression.

Livagen: Liver and Metabolic Research

Livagen is a tetrapeptide (Lys-Glu-Asp-Ala) studied in animal models of liver function. Reported effects include modulation of hepatocyte gene expression and effects on hepatic enzymes in aged animals.

Other Classes: Vesugen, Pinealon, Thymogen, Epitalon

• Vesugen(Lys-Glu-Asp): vascular tissue research.
• Pinealon(Glu-Asp-Arg): pineal gland and central nervous system research.
• Thymogen(Glu-Trp): thymus and immune research.
• Epitalon(Ala-Glu-Asp-Gly): pineal gland and longevity research; the most studied bioregulator with the largest English-language literature footprint.

Each compound is associated with a particular source tissue and a particular set of effects in animal model studies.

Proposed Mechanisms: Receptors, Gene Regulation, and Signal Transduction

The mechanism by which bioregulators produce their reported effects has been debated since the initial discoveries.

Receptor-Mediated Versus Gene-Regulation Hypotheses

Two principal mechanism hypotheses appear in the literature:

1. Cell penetration and direct gene regulation. Short peptides penetrate the cell membrane, traffic to the nucleus, and bind directly to DNA sequences associated with tissue-specific genes. This is the original Khavinson hypothesis. Direct DNA binding has been reported in some published studies but has also drawn skepticism due to the absence of canonical sequence-specific recognition elements in such short peptides.
2. Receptor-mediated signaling at the cell surface. Bioregulators may engage cell surface receptors that activate signaling cascades, ultimately producing tissue-specific gene expression changes. This mechanism is more consistent with classical pharmacology but has not been definitively demonstrated for most bioregulators.

A hybrid model that combines surface signaling and intracellular activity is also possible.

Animal Model Studies: What Does Literature Show?

The animal model literature reports effects on gene expression patterns, tissue function markers, and survival in aged animals. Many studies are conducted in models of accelerated aging or in genetically aged animals, and report extensions of life span or improvements in tissue-specific endpoints.

Reproducibility across laboratories outside the original Russian institution has been variable. Independent replication is an active area of contemporary research.

Mechanistic Uncertainty: Why Exact MOA Remains Unclear

Several factors contribute to the continuing mechanistic uncertainty: short peptide ligands engaging unconventional targets are inherently difficult to characterize; the original literature is concentrated in non-English journals with limited reach; and direct binding studies between bioregulators and proposed cellular targets are technically demanding.

For researchers planning new mechanistic studies, the bioregulator class offers a substantial opportunity for original work, given the gaps in receptor identification and signaling pathway mapping.

Literature Review: Quantity, Quality, and Geographic Distribution

The bioregulator literature has unusual geographic and language distributions that affect how researchers approach citation work.

Russian Literature Dominance: Publications and Accessibility

The bulk of bioregulator publications are in Russian-language journals, including Buletin of Experimental Biology and Medicine, Advances in Gerontology, and several others. Many of these articles are abstracted in English on PubMed but not fully translated. Researchers conducting comprehensive literature reviews on bioregulators may need to engage Russian-language sources or specialist databases.

English-Language Studies: Growing but Limited Coverage

English-language coverage has grown over the past decade. Reviews in international gerontology journals provide accessible summaries (Anisimov and Khavinson, 2010; PMID 20019471). Original research articles in English are increasing but remain a minority of the total literature.

Citation Patterns and Reproducibility Concerns

Citation patterns in the bioregulator literature differ from typical pharmacology research. Many papers cite a relatively small core set of foundational publications. Independent replication outside the original research group is an ongoing concern that contemporary researchers should be aware of when designing experiments.

Research Applications and Current Investigation Trends

Bioregulators continue to attract research attention in several areas.

Gerontology and Longevity Research: Primary Focus

The principal application of bioregulator research is gerontology, particularly studies of accelerated aging, age-related tissue dysfunction, and longevity in animal model systems. Epitalon has been the most widely studied compound in this context.

Tissue Repair and Regeneration Models

Bioregulators are also studied in tissue repair models, particularly for cartilage (Cartalax), vascular tissue (Vesugen), and pineal-mediated processes (Pinealon, Epitalon).

Combination Studies and Co-Administration Research

Some studies investigate combinations of two or more bioregulators administered concurrently, exploring potential additive or synergistic effects in animal models. The research-context framing for such studies emphasizes mechanism investigation rather than therapeutic application.

Also Read: Regulatory Landscape for Research Peptides in the United States: FDA, FTC, DEA

Frequently Asked Questions

What is a bioregulator peptide?

A bioregulator peptide is a short peptide (typically 2 to 6 residues) hypothesized to regulate gene expression and function in a specific tissue. The Khavinson class is the most extensively studied. The class is defined by an unusual proposed mechanism of action involving direct cellular and possibly nuclear effects rather than canonical surface receptor signaling.

Are bioregulator peptides approved by the FDA?

Most bioregulators are not FDA-approved as drugs. They are sold as research chemicals in the United States and have varying regulatory status in other countries; some are registered as pharmaceuticals in Russia and certain post-Soviet states. Researchers should verify regulatory status in their jurisdiction before sourcing.

Is there good scientific evidence for bioregulator effects?

The evidence base is substantial in Russian-language literature on animal model studies. English-language peer-reviewed coverage has grown but remains limited compared to better-studied research peptide classes. Mechanistic understanding is incomplete, and independent replication outside the originating laboratories is an ongoing area of investigation. Researchers should approach the literature with the same critical lens applied to any specialized field.

Why are Cartalax, Vilon, and Livagen so inexpensive compared to other research peptides?

Bioregulators are short sequences (2 to 6 residues), which makes solid-phase peptide synthesis fast and economical. Demand is also lower than for high-profile peptides such as the GLP-1 family, so suppliers face less competitive pressure on pricing. Lower price does not imply lower quality if the supplier provides a complete COA documenting purity and identity.

Are bioregulator peptides safe for animal research?

Most animal model studies report good tolerability at the doses used. Independent safety pharmacology data is limited compared to better-characterized peptide classes. Researchers planning bioregulator work should consult their institutional animal care and use committee, review the available preclinical literature, and source from suppliers with documented quality programs.

Also read: Browse verified peptide lab reports (COAs)

What are bioregulator peptides?

Bioregulator peptides are short peptides, typically two to four residues, associated in the published literature with particular tissues. The class is named for the research program that characterized it, and the compounds are studied largely in cell-culture and animal-model systems.

What is Epithalon?

Epithalon is a four-residue peptide associated in the published literature with pineal tissue. Published work has examined telomerase activity and telomere length in cultured human cell lines, and gene expression in cultured mesenchymal stem cells. These are cell-culture observations.

References

1. Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429.
2. Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon: a bioactive pineal tetrapeptide. Int J Mol Sci. 2025;26(6). PMID 40141333.
3. Ashapkin V, Khavinson V, Shilovsky G, Linkova N, Vanuyshin B. Gene expression in human mesenchymal stem cell aging cultures: modulation by short peptides. Mol Biol Rep. 2020;47(6):4323-4329. PMID 32399807.
4. Sokolova IB, Ryzhak GA, Mel’nikova NN, Sergeev IV, Khavinson VKh. Effects of Vascular Peptide Bioregulator on the Density of Microvascular Network in the Brain Cortex of Aged Rats. Bull Exp Biol Med. 2016;161(2):300-3. PMID 27383168.
5. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. PMID 20019471.
6. Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682.
7. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID 12048635.
8. Khavinson VKh, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. PMID 27905064.
9. Anisimov VN, Khavinson VKh, Morozov VG. Twenty years of study on effects of pineal peptide preparation: epithalamin in experimental gerontology and oncology. Ann N Y Acad Sci. 1994;719:483-493. PMID 8010618.

Research-only disclaimer. The peptides described in this article are sold and discussed for laboratory and research purposes only. They are not intended for human consumption, diagnostic use, or therapeutic application.

Educational notice. This article is for educational and informational purposes only and is intended for licensed researchers and laboratory professionals. The peptides discussed are research chemicals sold for laboratory and research applications. They are not intended for human consumption, diagnostic use, or therapeutic application.